= Investors

<= td width=3D100% height=3D372 valign=3Dtop align=3Dleft>
&n= bsp; Key Points about = WSCH:

The products and me= dical therapies developed by WSCH represent possibly the most important= breakthrough in the field of Dermatology in the last fifty years.&nbs= p;
WSCH anticipates= FDA approval on seven over-the-counter products within the next ye= ar, which will provide significant revenue in the retail drug market.
=
WSCH has experie= nced a success rate of 90% during clinical studies, completely elim= inating skin disease from 90% of all patients treated.
By year five, WSCH plans to have annua= lized revenue over $525 million and over $125 million in EBIT. This does not take into account income from OTC products which wi= ll be substantial.

<= /caption>
= Emergin= g Growth Stock Alert Wasatch Pharmaceuticals: A Company on the Rise

Company Name &n= bsp;	Wasatch Pharmaceuticals (OTCBB: WSCH)
Current = Price	$0.066
52-We= ek High	$27.50
5= 2-Week Low	$0.065

<= /div>
Company Background

Wasatch Pharmaceutical, Inc. is a fourteen year o= ld company with a record of outstanding achievements in the field of Derma= tology. Under the name of its subsidiary, American Institute of Skin= Care (AISC), Wasatch has operated two prototype clinics for the la= st five years where the products and medical therapies have been tested an= d proven on hundreds of patients. The Company's activities have been= centered on research in the area of serious skin diseases. A= concurrent discovery and benefit is WSCH's dramatic success in the area o= f skin rejuvenation. Seeing the high growth potential from major fun= ding, WSCH elected to become a public company less than two years a= go.
Wasatch's major successes i= n the area of skin diseases include:

Cystic Acne, Eczema= , Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea and= less prevalent skin diseases.

Interestingly, the= se skin disorders account for more than 70% of all business in the = field of dermatology for which there are very few (if any) safe, effective= therapies like those developed by Wasatch.

Because the th= erapies developed by Wasatch dominate this area of medicine, WSCH h= as elected to market its products via company-owned clinics throughout the= United States. This decision has resulted in the establishment of <= b>two research clinics in Utah for the purpose of implementing procedu= res within the clinics pursuant to testing and confirming the results that= were achieved in past clinical trials. Due to its success rate o= f 90% on hundreds of patients over a five year period, WSCH's clinics = are now on line with insurance providers independent of HMOs. Effort= s to establish Preferred Provider ship status with HMOs are presently bein= g pursued.

Most Recent WSCH News


Wasatch Pharmaceutical Inc. Announc= es a New Physician Marketing Campaign and Listing On German Stock Exchange= s MURRAY, Utah--(BUSINESS WIRE)--Nov.= 27, 2001--Wasatch Pharmaceutical Inc. (OTCBB:WSCH - news) CEO Gary Heesch announced today a marketing camp= aign directed to physicians. A direct link has been established on a physi= cian recruiting Web site making available therapies for the treatment of c= ystic acne, acne, folliculitis, and skin rejuvenation. Physicians will fin= d the benefits of these treatment therapies by logging on to the "= X Acne" link at physicianssearc= h.com. This physician search Web site typically receives over 2= 00,000 hits per month. Mr. Heesch reminded, "Our treatment therap= y products are also available via the AISC Online Store at restoremyskin.com.'" These skin treatment products come in kit form providing a = 90-day supply to patients for the full treatment program. Included in the = kit is an instructional video on the treatment therapy allowing the patien= t to use these products in their home. The therapies, when used as instruc= ted, achieve a success rate of eradication in excess of 90% with no sid= e effects of any consequence. Previously, these therapies and associat= ed products were only available through the two prototype clinics in Utah.= The availability of these products will open the way for family practitio= ners, pediatricians, internists and other primary care physicians to retai= n their patients under their care during the treatment of these common ski= n disorders. The benefit to insurance providers is the potential to sav= e millions of dollars in reimbursement costs by freeing the physician and = the patient from ongoing treatment. In the coming year, six additional therapies will be made availabl= e for a broad range of skin disorders that are badly in need of succes= sful therapies. Gary Heesch also an= nounced the listing of Wasatch Pharmaceutical stock on the Frankfurt an= d Berlin Exchanges in Germany. Active trading on these exchanges will = take place upon the completion of a research report in Germany. Said Mr. H= eesch, "We feel this is a significant event as Wasatch will gain w= ider exposure as a leader in dermatology and will put buying pressure on its stock to reflect the true value of a company t= hat has committed years of research and development of products that allow= people with serious skin disorders to live normal and more productive liv= es." There may be forward-loo= king statements in this release. Investors are cautioned that such forward= -looking statements involve risks and uncertainties, including, without li= mitation, continued acceptance of the Company's products, increased levels= of competition, new products introduced by competitors, changes in the ra= tes of subscriber acquisition and retention, and other risks detailed from= time to time in the Company's periodic reports filed with the Securities = and Exchange Commission.

Projections, Objectives, and Statistics

Over a five year period, AISC (WSCH's subsidiary) p= lans to establish 350 clinics in over 100 major population areas.&n= bsp; The company plans to hire over 150 medical doctors for these clinics,= train over 1,000 medical assistants and treat over 2,000,000 patients<= /b>. Also by year five, WSCH plans to have annualized over $525 million= in revenue and over $125 million in EBIT. This does not take into acc= ount income from OTC products which will be substantial.

<= blockquote>
As of 1991, there were = approximately 14 million chronic acne and eczema patients annually in the = United States, with the highest percentage between 18 to 44 years of = age. The actual number of patients with any type of acne is significa= ntly higher. Seven billion dollars is spent annually on derma= tological pharmaceutical products for these disorders.

= In 1994, the teen population reached 25 million. During the next d= ecade, it will grow at nearly twice the rate of
the overall p= opulation (according to U.S. Census Bureau projections). Acne pat= ients are primarily teenagers, whereas eczema patients range from inf= ants to the elderly.
A Look at the Competition
= Dermatologists are the primary competitors of WSCH's clinics. Dermatologis= ts specialize in the treatment of skin disorders and prescribe medications= to treat the disorder. However, competing products address the s= ymptoms of acne and eczema, not the cause.
<= font face=3DVerdana size=3D2>The competition's skin care treatments includ= e prescription medications (oral and external use drugs prescribed by derm= atologists and other doctors) and over-the-counter products.
Several common prescription medications include:
= 1) E-Mycin for oral and topical use, 2) Cleocin for oral and topical use, = 3) Tetracycline for oral and topical use, and 4) Accutane for oral use onl= y.

Over-the-counter acne medications include: = ;
1) Clearasil and Oxy creams, 2) generic brand creams, 3) medicat= ed pads, and 4) medicated soaps.

Many of the competit= ion's oral medications have serious side effects.
Costs for competing treatments range from $2.50 for= medicated soaps to $200 for Accutane oral medication prescription. = Treatments are on-going. Over time a person can spend an unlimite= d amount of money on such treatments. An example would be someon= e who spent $1,500 for a 22 week program of Accutane which includes blood = testing. Another example would be someone who has had acne for many = years and has spent in excess of $34,000.
At this time there is no known competitor who treats t= he causes of these skin disorders and no competitor can claim a success= rate equal to that of Wasatch's treatments.
Final Thoughts on WSCH<= /b>
Wi= th a proven success rate of 90% in a field that affects so many of our liv= es, Wasatch has clearly positioned itself in a market hungry and desper= ate for successful products and treatment. WSCH has recently exp= anded its marketing presence (as seen in the above press release) and will= continue to aggressively broaden awareness over the near term. The listin= g of WSCH on the German stock exchange is another sign of the compa= ny's credibility and ambitious plans to establish itself as a major glo= bal player in the field of dermatology.

WSCH has = taken on a completely different approach. By addressing the causes o= f skin disorders rather than the symptoms, WSCH will help to successfully = eliminate skin disease altogether. Given its

1. Successful = 14-year history and plans for expansion
2. Impressive revenue projecti= ons ($525 million+ annualized by year 5 and $125 million in EBIT)
= 3. Virtually unmatched success rate of 90%...

...and so much = more, WSCH will certainly watched by savvy investors for some time to come= .
DISCLAIMER= :
Information within this email contains "forward looking s= tatements" within the meaning of Section 27A of the Securities Act of= 1933 and Section 21B of the Securities Exchange Act of 1934. Any statemen= ts that express or involve discussions with respect to predictions, expect= ations, beliefs, plans, projections, objectives, goals, assumptions or fut= ure events or performance are not statements of historical fact and may be= "forward looking statements."

Forward looking statemen= ts are based on expectations, estimates and projections at the time the st= atements are made that involve a number of risks and uncertainties wh= ich could cause actual results or events to differ materially from those p= resently anticipated. Forward looking statements in this action may be ide= ntified through the use of words such as "projects", "fores= ee", "expects", "will," "anticipates," "estimates," "believes," "understands" o= r that by statements indicating certain actions "may,"= ; "could," or <= font face=3DVerdana size=3D1 color=3D#5F5F5F>"might" = occur. All information provided within this email pertaining to inve= sting, stocks, securities must be understood as information provided and n= ot investment advice. Emerging Growth Stock Alert advises all readers and = subscribers to seek advice from a registered professional securities = representative before deciding to trade in stocks featured within this ema= il. None of the material within this report shall be construed as an= y kind of investment advice.

In compliance with the Securities Ac= t of 1933, Section17(b), Emerging Growth Stock Alert discloses the receipt= of $40,000 cash from a third party for the publication of this report and= additional services related= to WSCH. Be aware of an inherent conflict of interest resulting from such= compensation. All factual information in this report was gathe= red from public sources, including but not limited to SEC filings, Company= Press Releases, and the company's website at wasatchpharm.com. Emerging Growth Stock Alert believes t= his information to be reliable but can make no guarantee as to its accurac= y or completeness. Use of the material within this email constitutes your = acceptance of these terms.

To b= e removed from future mailings, please respond
to this email with &qu= ot;Remove" in the subject line
<= /div> To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-newbies" in the body of the message

Wasatch Pharmaceutical Inc. Announc= es a New Physician Marketing Campaign and Listing On German Stock Exchange= s